SnapshotDx Quiz: May 2020 Study on BIVV009 in Bullous Pemphigoid
bullous pemphigoid autoimmune blistering disease histological examination immunofluorescence examination IgG complement deposition dermal-epidermal junction autoantibodies BP180 BP230 complement system BIVV009 C3c-positive biopsies complement component α-C3c hemolytic activity complement CH50 eosinophil infiltration
TLDR BIVV009 is a safe treatment for bullous pemphigoid that reduces C3 deposition without harmful side effects.
The "SnapshotDx Quiz: May 2020" document from the Journal of Investigative Dermatology focused on bullous pemphigoid (BP), an autoimmune blistering disease. The quiz confirmed BP diagnosis through histological and immunofluorescence examinations, highlighting IgG and complement deposition at the dermal-epidermal junction. It discussed the role of autoantibodies against BP180 and BP230 in activating the complement system. BIVV009 treatment showed no kidney or liver injuries, with mild side effects like common cold and fatigue. In patients with C3c-positive biopsies, BIVV009 led to the disappearance or reduction of complement component α-C3c staining in most patients and decreased hemolytic activity of complement CH50, though it did not significantly affect eosinophil infiltration. The study emphasized the need for further trials to assess the treatment's impact on BP symptoms.
